Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 1.01, 2.03, 3.03, 9.01 · 8-K

MOLECULAR TEMPLATES INC

Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Material Modification to Rights of Security Holders

Item 1.01 Entry into a Material Definitive Agreement Bridge Loan On February 20, 2025, Molecular Templates, Inc. (the “Company”) entered into a Loan and Security Agreement - Bridge Loan (the “Loan and Security Agreement”) among Molecular Templates OpCo, Inc.…

Filed Feb 26, 2025Accepted Feb 26, 2025, 12:27 PM ESTCIK 1183765Accession 0001493152-25-008399
Share

Company context

Historical securities (3)

Recent company filings

  1. 25-NSE - filed by Nasdaq Stock Market LLC regarding Molecular Templates, Inc.May 22, 2025
  2. Entry into a Material Definitive Agreement · Bankruptcy or Receivership · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Triggering Events That Accelerate or Increase a Direct Financial ObligationApr 24, 2025
  3. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsJan 2, 2025
  4. 8-K filingDec 19, 2024
  5. DEFA14A filingDec 4, 2024

Disclosure sections

Items 1.01, 2.03, 3.03, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement Bridge Loan On February 20, 2025, Molecular Templates, Inc. (the “Company”) entered into a Loan and Security Agreement - Bridge Loan (the “Loan and Security Agreement”) among Molecular Templates OpCo, Inc. (“Opco”), as borrower, the Company (“Borrower Representative”, together with Opco, collectively “Borrowers”), the lenders from time to time party thereto (collectively, the “Lenders”), K2 HealthVentures LLC (“K2”), as administrative agent for Lenders (in such capacity, together with its successors, “Administrative Agent”), and Ankura Trust Company, LLC (“Ankura” or “Collateral Trustee”), as collateral trustee for Lenders, Collateral Trustee, and Administrative Agent. Amount. Pursuant to the Loan and Security Agreement, the Lenders agreed to extend to the Company (i) an initial loan of $560,000 which was drawn on the closing date (the “Initial Bridge Loan”) and (ii) subject to Lenders’ approval in each Lender’s sole and absolute discretion and the terms and conditions of the Loan and Security Agreement, each Lender may, severally and not jointly, upon written request by Borrower Representative, make to Borrowers additional advances from time to time in amounts as the parties may agree (collectively, “Discretionary Incremental Bridge Loans”, and together with the Initial Bridge Loan, the “Bridge Loans”, and each, a “Bridge Loan”). The Borrower shall use the proceeds of the Bridge Loans to pay expenses in accordance with the permitted disbursements described on Schedule 1 of the Loan and Security Agreement or in accordance with Administrative Agent’s prior written approval from time to time. Maturity. The Initial Bridge Loan matures on April 21, 2025 (the “Maturity Date”), unless accelerated pursuant to an event of default, as described below. All amounts outstanding under the Loan and Security Agreement will be due and payable upon the earlier of the maturity date or the acceleration of the loans and commitments upon an event of default. Interest Rate. Amounts borrowed under the Bridge Loan bear interest at a fixed rate of 13.5% per annum. Interest shall accrue and be capitalized monthly on the first calendar day of each month and added to the principal amount outstanding on such date. Security. the Borrowers’ obligations are secured by a first priority, perfected lien on substantially all the property and assets of the Borrowers including, without limitation, their intellectual property and including their wholly-owned domestic subsidiaries (the “Collateral”) except for certain other customary excluded assets as set forth therein. Covenants; Representations and Warranties; Other Provisions. The Loan and Security Agreement contains customary representations, warranties and covenants, including but not limited to covenants by Borrowers limiting additional indebtedness, liens, mergers and acquisitions, dispositions, investments, distributions, subordinated debt, transactions with affiliates and fundamental changes as described in the Loan and Security Agreement. Default Provisions. The Loan and Security Agreement provides for events of default customary for loan of this type, including but not limited to non-payment, defaults on other debt, misrepresentation, breach of covenants, representations and warranties, insolvency, bankruptcy, certain uncured judgments and the occurrence of a material adverse effect on the Company. Immediately upon the occurrence and during the continuation of an event of default, all outstanding obligations under the Loan and Security Agreement shall accrue interest at the Interest Rate plus 5%. Upon the occurrence and continuation of any event of default, the Administrative Agent may accelerate payment of all obligations and terminate the Lenders’ commitments under the Loan and Security Agreement. Amended CVR Agreement Concurrent with entry into the Loan and Security Agreement, on February 20, 2025, the Company entered into an amended and restated secured contingent value right agreement (the “Amended CVR Agreement”), by and among Opco, the Company, K2, as holder (“Holder”), and Ankura, as collateral trustee for Holder and Ankura. The Amended CVR Agreement amends, restates and replaces in its entirety that certain convertible secured contingent value right agreement, among the parties, dated as of June 16, 2023 (the “Original CVR Agreement”), which was initially entered into in connection with the refinancing of certain loan obligations of Opco and the Company to K2. The obligations under the Amended CVR Agreement remain secured by a security interest in the Collateral. The Amended CVR Agreement also fixes a repayment maturity date of February 1, 2026. The above descriptions of the Loan and Security Agreement and Amended CVR Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the Loan and Security Agreement and the Amended CVR Agreement, copies of which are filed as Exhibits 10.1 and 10.2 hereto and are incorporated by reference herein.
Item 2.03Item 2.03 - Creation of Direct Financial Obligation
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information contained in Item 1.01 under the headings “Bridge Loan” and “Amended CVR Agreement” is incorporated by reference into this Item 2.03.
Item 3.03Item 3.03 - Material Modification to Rights
Item 3.03 Material Modifications to Rights of Security Holders The information in Item 1.01 above is incorporated by reference into this Item 3.03. Cautionary Information Regarding Trading in the Company’s Securities The Company cautions that trading in the Company’s securities is highly speculative and poses substantial risks. Trading prices for the Company’s securities currently bear little or no relationship to the actual value that may be realized, if any, by holders of the Company’s securities. The Company does not currently expect that the holders of its securities will receive value for their investment. The Company also does not currently expect to have the necessary resources to continue its reporting obligations. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.